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SUMMARY. A simple, efficient and reliable capillary zone electrophoresis method with diode array detec-
tion was developed and validated for the simultaneous determination of olmesartan medoxomil and am-
lodipine besylate in their binary mixtures. The optimum separation for these compounds was achieved
with a fused - silica capillary column (i.d. 75.0 μm, total length 48.5 cm and effective length 40.0 cm) and
40.0 mM citrate buffer at pH 6.0 as the running buffer. The samples were injected hydrodynamically for 3
s at 50 mbar and applied voltage was + 15 kV at 30 °C capillary temperature. Detection wavelength was
set at 235 nm. Valsartan was used as internal standard. The method was validated with respect to stability,
linearity, sensitivity, precision, accuracy, recovery and selectivity. The linear calibration range was found
to be 2.00 - 30.00 μg/mL for olmesartan medoxomil and amlodipine besylate. The limits of detection
(LOD) were 0.05 μg/mL for both compounds. The relative standard deviations (RSD) of the proposed
method ranged between 1.51 and 2.49 % for intra-day precision and 1.51 and 3.73 % for inter-day preci-
sion. The developed and validated method successfully applied for the simultaneous determination of
olmesartan medoxomil and amlodipine besylate in their pharmaceutical formulations. 
